MindRank's AI-Driven Drug Discovery Platform Paper Published in Autophagy (IF=14.3)

This study focuses on two major challenges in the treatment of Alzheimer’s disease (AD): existing mTOR-dependent autophagy inducers cause widespread side effects affecting cellular metabolism and exhibit poor blood-brain barrier penetration. Leveraging its proprietary AI drug discovery platform, MindRank has developed a mechanism-oriented AI screening system named DeepDrugDiscovery.

The system# TitleFrom the Traditional “Structure-Based Screening” Drug Discovery Paradigm to a “Mechanism-Oriented” Intelligent Screening Strategy; integrating predictions of absorption, distribution, metabolism, excretion, and toxicity (ADMET) properties with blood-brain barrier permeability prediction, thereby achieving an end-to-end workflow from large-scale virtual screening to experimental validation, significantly accelerating the drug discovery process.

As an open-source resource sharing,DeepDrugDiscovery demonstrates the immense potential of AI platforms and computational workflows to assist scientists and researchers in mechanism-driven drug discovery within high-demand disease areas.，Provides a novel pathway for the treatment of complex neurological disorders such as Alzheimer’s disease.